Who Generates Higher Gross Profit? Novo Nordisk A/S or Alkermes plc

A Tale of Two Giants: Novo Nordisk A/S vs. Alkermes plc

In the competitive landscape of the pharmaceutical industry, Novo Nordisk A/S and Alkermes plc stand as prominent players. Over the past decade, Novo Nordisk has consistently outperformed Alkermes in terms of gross profit. From 2014 to 2023, Novo Nordisk's gross profit surged by approximately 165%, reaching a staggering 196 billion in 2023. In contrast, Alkermes saw a more modest increase of around 725%, culminating in a gross profit of 1.4 billion in the same year.

This stark difference highlights Novo Nordisk's dominant market position, driven by its strong portfolio in diabetes care and other chronic diseases. Meanwhile, Alkermes, with its focus on central nervous system disorders, has shown impressive growth, albeit on a smaller scale. As the industry evolves, these companies continue to shape the future of healthcare with their innovative solutions.